ArticleCureus2026
Epithelial Neuroendocrine Neoplasms: Grading Based on the New WHO 2022 Guidelines.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) are rare. Epithelial NETs are generally considered slow-growing tumors. Arising from neuroendocrine cells, NETs can develop at various primary sites in the body. Gastrointestinal NETs are the most common of all NETs. The ileum, appendix, and rectum are among the most common sites, followed by the colon, stomach, and duodenum; some series report a female preponderance. Bronchopulmonary NETs are relatively rare and are often indolent in nature. In recent decades, the incidence has been rising. This may be due to greater awareness, improved diagnostic tools, or changes in definitions/classification. Grading of epithelial neuroendocrine neoplasms is beneficial, as it allows tumors to be graded by proliferative activity and distinguished from neuroendocrine carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.